LNTH Lantheus Holdings, Inc.
Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR Lantheus Holdings, Inc. (LNTH) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • Newly added risk: Loss of transitional pass-through payment status (TPT Status) for PYLARIFY as of December 31, 2024, impacting reimbursement and competitiveness
- • Most materially updated risk: CMS 2025 OPPS Rule unbundled diagnostic radiopharmaceutical payments, reducing PYLARIFY’s payment rate to below prior ASP-based amount, changing competitive dynamics
Quarterly Financial SummaryXBRL
Revenue
$384M
Net Income
$28M
Gross Margin
57.9%
Operating Margin
11.4%
Net Margin
7.2%
ROE
2.5%
Total Assets
$2.3B
Source: XBRL data from Lantheus Holdings, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Lantheus Holdings, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.